Combination Therapy with Secretome of Reovirus-Infected Mesenchymal Stem Cells and Metformin Improves Anticancer Effects of Irinotecan on Colorectal Cancer Cells in vitro

• Published in: Intervirology Vol. 68; no. 1; pp. 1 - 16
• Main Authors: Elhamipour, Maliheh, Soleimanjahi, Hoorieh, Abdoli, Asghar, Sharifi, Negar, Karimi, Hesam, Soleyman Jahi, Saeed, Kvistad, Ruth
• Format: Journal Article
• Language: English
• Published: Switzerland S. Karger AG 01.01.2025; Karger Publishers
• Subjects: Animals; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Cell Line, Tumor; Cell Survival - drug effects; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - therapy; Combined Modality Therapy; Irinotecan - pharmacology; Mesenchymal Stem Cells - drug effects; Mesenchymal Stem Cells - virology; Metformin - pharmacology; Mice; Oncolytic Virotherapy - methods; Reoviridae - drug effects; Reoviridae - physiology; Irinotecan; Colorectal cancer cells; Metformin; Reovirus; Mesenchymal stem cells

Introduction: Irinotecan, a topoismorase 1 inhibitor, has been used for the treatment of colorectal cancer. It was shown that monotherapy alone is largely ineffective. The combination therapy was used for antitumor activity. The synergistic anticancer effects of oncolytic reovirus-infected secretome...